文献速递银屑病与炎症性皮肤病

一项多中心、前瞻性、观察性研究:在希腊常规诊疗环境中,体质指数和腰围等危险因素对接受英夫利西单抗治疗的中重度斑块型银屑病患者生活质量改善和临床应答的影响

A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-01-01

该多中心前瞻性观察性研究纳入希腊21家皮肤科医院或私人诊所的136例中重度斑块型银屑病患者,在开始英夫利西单抗治疗后随访至约54周。结果显示英夫利西单抗可降低疾病活动度并改善生活质量,且入组时BMI类别和腹型肥胖不影响PASI 75或DLQI改善率的达成。

要点

  • 英夫利西单抗治疗中重度斑块型银屑病至1年可降低疾病活动度并改善生活质量。
  • 入组时BMI类别和腹型肥胖不影响PASI 75或DLQI改善率的达成。
  • 腰围与基线PASI呈低度相关(ρ=0.324,P<0.001)。

核心结论

  • 在希腊常规诊疗中,英夫利西单抗通过1年治疗降低中重度银屑病患者疾病活动度并改善生活质量,且不依赖于其BMI和腰围。

研究设计与样本

  • 多中心、前瞻性、观察性研究,纳入2012年10月至2014年6月期间由21家皮肤科医院或私人诊所招募的136例成年中重度斑块型银屑病患者,患者在入组前2周内开始使用原研英夫利西单抗治疗。
  • 入组后访视分别在治疗开始后14±4周、30±4周和54±4周进行。

主要发现

  • 入组时中位年龄48.6岁,中位BMI 29.6 kg/m2,中位腰围107.0 cm;62.5%为男性,62.5%为生物制剂初治。
  • 基线平均PASI评分为23.4±13.6,平均DLQI评分为15.0±8.3。
  • 入组时腰围与基线PASI呈低度相关(ρ=0.324,P<0.001)。
  • 在中位48.4周的英夫利西单抗暴露期间,符合方案集有89.3%的患者达到PASI 75应答。
  • 第14、30和54周时PASI 75达标率分别为66.4%、74.8%和76.6%;有临床意义的DLQI改善(下降≥5分)率分别为68.9%、75.7%和69.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity has been associated with moderate-to-severe plaque psoriasis severity and PASI 75 response attainment of biologic therapies, but findings are inconsistent. OBJECTIVE: This study aimed to examine the association of body mass index (BMI) and waist circumference (WC) on disease severity, to identify potential patient characteristics associated with response attainment and to assess the impact of infliximab on the patients' health-related quality of life (HRQoL) among infliximab-treated patients in the routine care setting of Greece. METHODS: This was a multicenter, prospective, observational study of adult moderate-to-severe plaque psoriasis patients who had initiated treatment with originator infliximab within 2 weeks prior to enrolment. Postenrolment visits occurred at 14 ± 4, 30 ± 4 and 54 ± 4 weeks following treatment onset. RESULTS: Between October 2012 and June 2014, 136 eligible patients (62.5% males) with a median age of 48.6 years, BMI of 29.6 kg/m2 and WC of 107.0 cm at enrolment were recruited by 21 dermatology hospital/private offices. All patients had received prior psoriasis treatment(s); 62.5% were biologic-naïve. Mean baseline psoriasis area severity index (PASI) and Dermatology Quality of Life Index (DLQI) scores were 23.4 ± 13.6 and 15.0 ± 8.3, respectively. A low correlation was observed between WC at enrolment and baseline PASI [ρ = 0.324 (P < 0.001)]. Over a median 48.4 weeks of infliximab exposure, 89.3% of the per protocol set achieved a PASI 75 response. At 14, 30 and 54 weeks, the PASI 75 attainment rate was 66.4%, 74.8% and 76.6%, respectively; the clinically meaningful DLQI improvement (≥5 point decrease) rate was 68.9%, 75.7% and 69.8%, respectively. BMI category and abdominal obesity at enrolment did not impact PASI 75 or DLQI improvement rate attainment. CONCLUSION: In the routine care of Greece, infliximab reduced disease activity and improved the quality of life of moderate-to-severe psoriasis patients through 1 year of treatment, independent of their BMI and WC.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Petridis A, Panagakis P, Moustou E, et al. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece. J Eur Acad Dermatol Venereol. 2018. PMID: 29356149. doi:10.1111/jdv.14802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。